Are statin medications safe in patients with ALS?
Statin medications for elevated cholesterol are one of the most commonly prescribed medications worldwide. The aim of this study was to determine if statin medications affect the rate of disease progression, the severity and frequency of muscle cramping, and serum CK levels in patients with ALS. We conducted a prospective cohort study in patients diagnosed with ALS with statin medication as the predetermined exposure variable and the rate of decline of the ALS Functional Rating Scale-Revised (ALSFRS-R) as the primary outcome. One hundred and sixty-four consecutive patients with laboratory supported probable, clinically probable, or clinically definite ALS were evaluated from January 2006 to September 2007. Thirty-two patients (20%) were taking statin medications and 132 were in the control group. After adjusting for covariates, we found a highly significant increase in the rate of decline in the ALSFRS-R for the statin group (1.71 units/month) compared to the control group (1.05 units/month, pB0.0001) representing a 63% increase in the rate of functional decline. Patients on statin therapy also reported a significant increase in muscle cramp frequency and severity (pB0.0001). This study has demonstrated a strong association between statin medications and an increased rate of functional decline and muscle cramping in patients with ALS. Although this association does not prove a causal relationship, it is prudent to exercise caution and discuss discontinuation or replacement of statin medications in patients with ALS.
Zinman
Lorne
L
ALS/Neuromuscular Clinic, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada. lorne.zinman@sunnybrook.ca
Sadeghi
Reza
R
Gawel
Marek
M
Patton
Dan
D
Kiss
Alex
A
D000368:Aged; D000690:Amyotrophic Lateral Sclerosis / Q000503:physiopathology; D000924:Anticholesteremic Agents; D000075202:Contraindications; D003402:Creatine Kinase / Q000097:blood; D018450:Disease Progression; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008297:Male; D008875:Middle Aged; D009120:Muscle Cramp / Q000503:physiopathology; D011446:Prospective Studies; D014797:Vital Capacity
D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D003402:Creatine Kinase